Gene transfer studies in animals: What do they really tell us about the prospects for gene therapy in DMD?

Neuromuscular Disorders

Volumn 12, Issue SUPPL., 2002, Pages

  Wells, Dominic J ^a   Wells, Kim E ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Duchenne muscular dystrophy; Dystrophin; Gene therapy; mdx; Plasmid; Viral vectors

Indexed keywords

DYSTROPHIN; INTEGRIN; UTROPHIN;

CONFERENCE PAPER; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; GENE DELIVERY SYSTEM; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GERM LINE; HEART MUSCLE; HUMAN; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; SKELETAL MUSCLE; TRANSGENIC ANIMAL;

ANIMALS; CYTOSKELETAL PROTEINS; DNA, RECOMBINANT; DYSTROPHIN; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INTEGRINS; MEMBRANE PROTEINS; MICE; MICE, INBRED MDX; MUSCLES; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, DUCHENNE; UTROPHIN;

EID: 0036823755     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(02)00077-9     Document Type: Conference Paper

References (129)

1. Emery AEH. Duchenne Muscular Dystrophy. Oxford Monog Med Genet No 15, Oxford Medical, 1987.
2. Simonds A.K., Ward S., Heather S., Bush A., Muntoni F. Outcome of paediatric domiciliary mask ventilation in neuromuscular and skeletal disease. Eur Respir J. 16:2000;476-481.
3. Hoffman E.P., Brown R.H. Jr, Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 51:1987;919-928.
4. Hoffman E.P., Fischbeck K.H., Brown R.H., et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med. 318:1988;1363-1368.
5. Koenig M., Beggs A.H., Moyer M. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 45:1989;498-506.
6. Bushby K.M. The limb-girdle muscular dystrophies-multiple genes, multiple mechanisms. Hum Mol Genet. 8:1999;1875-1882.
7. Bulfield G., Siller W.G., Wight P.A., Moore K.J. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA. 81:1984;1189-1192.
8. Sicinski P., Geng Y., Ryder-Cook A.S., Barnard E.A., Darlison M.G., Barnard P.J. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 244:1989;1578-1580.
9. Lefaucheur J.P., Pastoret C., Sebille A. Phenotype of dystrophinopathy in old mdx mice. Anat Rec. 242:1995;70-76.
10. Stedman H.H., Sweeney H.L., Shrager J.B., et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature. 352:1991;536-539.
11. Chapman V.M., Miller D.R., Armstrong D., Caskey C.T. Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc Natl Acad Sci USA. 86:1989;1292-1296.
12. Danko I., Chapman V., Wolff J.A. The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy. Pediatr Res. 32:1992;128-131.
13. Wertz K., Fuchtbauer E.M. Dmd (mdx-beta geo): a new allele for the mouse dystrophin gene. Dev Dyn. 212:1998;229-241.
14. Deconinck A.E., Potter A.C., Tinsley J.M., et al. Postsynaptic abnormalities at the neuromuscular junctions of utrophin-deficient mice. J Cell Biol. 136:1997;883-894.
15. Grady R.M., Merlie J.P., Sanes J.R. Subtle neuromuscular defects in utrophin-deficient mice. J Cell Biol. 136:1997;871-882.
16. Deconinck A.E., Rafael J.A., Skinner J.A., et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell. 90:1997;717-727.
17. Grady R.M., Teng H., Nichol M.C., Cunningham J.C., Wilkinson R.S., Sanes J.R. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell. 90:1997;729-738.
18. Cooper B.J., Winand N.J., Stedman H., et al. The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature. 334:1988;154-156.
19. Kornegay J.N., Tuler S.M., Miller D.M., Levesque D.C. Muscular dystrophy in a litter of golden retriever dogs. Muscle Nerve. 11:1988;1056-1064.
20. Sharp N.J., Kornegay J.N., Van Camp S.D., et al. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics. 13:1992;115-121.
21. Schatzberg S.J., Olby N.J., Breen M., et al. Molecular analysis of a spontaneous dystrophin 'knockout' dog. Neuromuscul Disord. 9:1999;289-295.
22. Martin H., Ontell M. Regeneration of dystrophic muscle following multiple injections of bupivacaine. Muscle Nerve. 11:1988;588-596.
23. Cox G.A., Sunada Y., Campbell K.P., Chamberlain J.S. Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy. Nat Genet. 8:1994;333-339.
24. Greenberg D.S., Sunada Y., Campbell K.P., Yaffe D., Nudel U. Exogenous Dp71 restores the levels of dystrophin associated proteins but does not alleviate muscle damage in mdx mice. Nat Genet. 8:1994;340-344.
25. Matsuda R., Nishikawa A., Tanaka H. Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. J Biochem (Tokyo). 118:1995;959-964.
26. McArdle A., Edwards R.H., Jackson M.J. Time course of changes in plasma membrane permeability in the dystrophin-deficient mdx mouse. Muscle Nerve. 17:1994;1378-1384.
27. Gillis J.M. Understanding dystrophinopathies: an inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse. J Muscle Res Cell Motil. 20:1999;605-625.
28. England S.B., Nicholson L.V., Johnson M.A., et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature. 343:1990;180-182.
29. Acsadi G., Dickson G., Love D.R., et al. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature. 352:1991;815-818.
30. Wang B., Li J., Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA. 97:2000;13714-13719.
31. Yuasa K., Ishii A., Miyagoe Y., Takeda S. Introduction of rod-deleted dystrophin cDNA, delta DysM3, into mdx skeletal muscle using adenovirus vector (in Japanese). Nippon Rinsho. 55:1997;3148-3153.
32. Fabb S.A., Wells D.J., Serpente P., Dickson J.G. Adeno-associated virus vector transfer of a human microdystrophin construct into nude/mdx mice effectively restores dystrophin and dystrophin-associated proteins at the sarcolemma. Human Mol Genet. 11:2002;733-741.
33. Harper S.Q., Hauser M.A., DelloRusso C., et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 8:2002;253-261.
34. Lin S., Burgunder J.M. Utrophin may be a precursor of dystrophin during skeletal muscle development. Brain Res Dev Brain Res. 119:2000;289-295.
35. Helliwell T.R., Man N.T., Morris G.E., Davies K.E. The dystrophin-related protein, utrophin, is expressed on the sarcolemma of regenerating human skeletal muscle fibres in dystrophies and inflammatory myopathies. Neuromuscul Disord. 2:1992;177-184.
36. Wells D.J., Wells K.E., Walsh F.S., et al. Human dystrophin expression corrects the myopathic phenotype in transgenic mdx mice. Hum Mol Genet. 1:1992;35-40.
37. Lee C.C., Pons F., Jones P.G., et al. Mdx transgenic mouse: restoration of recombinant dystrophin to the dystrophic muscle. Hum Gene Ther. 4:1993;273-281.
38. Cox G.A., Cole N.M., Matsumura K., et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature. 364:1993;725-729.
39. Rafael J.A., Sunada Y., Cole N.M., Campbell K.P., Faulkner J.A., Chamberlain J.S. Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform. Hum Mol Genet. 3:1994;1725-1733.
40. Wells D.J., Wells K.E., Asante E.A., et al. Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Hum Mol Genet. 4:1995;1245-1250.
41. Phelps S.F., Hauser M.A., Cole N.M., et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet. 4:1995;1251-1258.
42. Rafael J.A., Cox G.A., Corrado K., Jung D., Campbell K.P., Chamberlain J.S. Forced expression of dystrophin deletion constructs reveals structure-function correlations. J Cell Biol. 134:1996;93-102.
43. Corrado K., Rafael J.A., Mills P.L., et al. Transgenic mdx mice expressing dystrophin with a deletion in the actin-binding domain display a 'mild Becker' phenotype. J Cell Biol. 134:1996;873-884.
44. Crawford G.E., Faulkner J.A., Crosbie R.H., Campbell K.P., Froehner S.C., Chamberlain J.S. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol. 150:2000;1399-1410.
45. Ahmad A., Brinson M., Hodges B.L., Chamberlain J.S., Amalfitano A. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy. Hum Mol Genet. 9:2000;2507-2515.
46. Turkel S.B., Howell R., Iseri A.L., Chui L. Ultrastructure of muscle in fetal Duchenne's dystrophy. Arch Pathol Lab Med. 105:1981;414-418.
47. Tinsley J.M., Potter A.C., Phelps S.R., Fisher R., Trickett J.I., Davies K.E. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature. 384:1996;349-353.
48. Deconinck N., Tinsley J., De Backer F., et al. Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice. Nat Med. 3:1997;1216-1221.
49. Tinsley J., Deconinck N., Fisher R., et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med. 4:1998;1441-1444.
50. Fisher R., Tinsley J.M., Phelps S.R., et al. Non-toxic ubiquitous over-expression of utrophin in the mdx mouse. Neuromuscul Disord. 11:2001;713-721.
51. Burkin D.J., Wallace G.Q., Nicol K.J., Kaufman D.J., Kaufman S.J. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J Cell Biol. 152:2001;1207-1218.
52. Wehling M., Spencer M.J., Tidball J.G. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol. 155:2001;123-131.
53. Ragot T., Vincent N., Chafey P., et al. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature. 361:1993;647-650.
54. Vincent N., Ragot T., Gilgenkrantz H., et al. Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. Nat Genet. 5:1993;130-134.
55. Alameddine H.S., Quantin B., Cartaud A., Dehaupas M., Mandel J.L., Fardeau M. Expression of a recombinant dystrophin in mdx mice using adenovirus vector. Neuromuscul Disord. 4:1994;193-203.
56. Clemens P.R., Krause T.L., Chan S., Korb K.E., Graham F.L., Caskey C.T. Recombinant truncated dystrophin minigenes: construction, expression, and adenoviral delivery. Hum Gene Ther. 6:1995;1477-1485.
57. Acsadi G., Lochmuller H., Jani A., et al. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum Gene Ther. 7:1996;129-140.
58. Deconinck N., Ragot T., Marechal G., Perricaudet M., Gillis J.M. Functional protection of dystrophic mouse (mdx) muscles after adenovirus-mediated transfer of a dystrophin minigene. Proc Natl Acad Sci USA. 93:1996;3570-3574.
59. Lochmuller H., Petrof B.J., Pari G., et al. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Ther. 3:1996;706-716.
60. Jani A., Lochmuller H., Acsadi G., et al. Generation, validation, and large scale production of adenoviral recombinants with large size inserts such as a 6.3 kb human dystrophin cDNA. J Virol Methods. 64:1997;111-124.
61. Zhao J.E., Lochumuller H., Nalbantoglu J., et al. Study of adenovirus-mediated dystrophin minigene transfer to skeletal muscle by combined microscopic display of adenoviral DNA and dystrophin. Hum Gene Ther. 8:1997;1565-1573.
62. Howell J.M., Lochmuller H., O'Hara A., et al. High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression. Hum Gene Ther. 9:1998;629-634.
63. Guibinga G.H., Lochmuller H., Massie B., Nalbantoglu J., Karpati G., Petrof B.J. Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles. J Virol. 72:1998;4601-4609.
64. Yang L., Lochmuller H., Luo J., et al. Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) mice. Gene Ther. 5:1998;369-379.
65. Yuasa K., Miyagoe Y., Yamamoto K., Nabeshima Y., Dickson G., Takeda S. Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs. FEBS Lett. 425:1998;329-336.
66. Ebihara S., Guibinga G.H., Gilbert R., et al. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice. Physiol Genomics. 3:2000;133-144.
67. O'Hara A.J., Howell J.M., Taplin R.H., et al. The spread of transgene expression at the site of gene construct injection. Muscle Nerve. April 24:(4):2001;488-495.
68. Guibinga G.H., Ebihara S., Nalbantoglu J., Holland P., Karpati G., Petrof B.J. Forced myofiber regeneration promotes dystrophin gene transfer and improved muscle function despite advanced disease in old dystrophic mice. Mol Ther. 4:2001;499-507.
69. Haecker S.E., Stedman H.H., Balice-Gordon R.J., et al. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther. 7:1996;1907-1914.
70. Kumar-Singh R., Chamberlain J.S. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum Mol Genet. 5:1996;913-921.
71. Kochanek S., Clemens P.R., Mitani K., Chen H.H., Chan S., Caskey C.T. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA. 93:1996;5731-5736.
72. Clemens P.R., Kochanek S., Sunada Y., et al. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. 3:1996;965-972.
73. Chen H.H., Mack L.M., Choi S.Y., Ontell M., Kochanek S., Clemens P.R. DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. Hum Gene Ther. 10:1999;365-373.
74. Gilbert R., Nalbantoglu J., Howell J.M., et al. Dystrophin expression in muscle following gene transfer with a fully deleted ('gutted') adenovirus is markedly improved by trans-acting adenoviral gene products. Hum Gene Ther. 12:2001;1741-1755.
75. Akkaraju G.R., Huard J., Hoffman E.P., et al. Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle. J Gene Med. 1:1999;280-289.
76. Dunckley M.G., Wells D.J., Walsh F.S., Dickson G. Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo. Hum Mol Genet. 2:1993;717-723.
77. Fassati A., Wells D.J., Sgro Serpente P.A., et al. Genetic correction of dystrophin deficiency and skeletal muscle remodeling in adult MDX mouse via transplantation of retroviral producer cells. J Clin Invest. 100:1997;620-628.
78. Gilbert R., Nalbanoglu J., Tinsley J.M., Massie B., Davies K.E., Karpati G. Efficient utrophin expression following adenovirus gene transfer in dystrophic muscle. Biochem Biophys Res Commun. 242:1998;244-247.
79. Gilbert R., Nalbantoglu J., Petrof B.J., et al. Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum Gene Ther. 10:1999;1299-1310.
80. Wakefield P.M., Tinsley J.M., Wood M.J., Gilbert R., Karpati G., Davies K.E. Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene. Gene Ther. 7:2000;201-204.
81. Feero W.G., Rosenblatt J.D., Huard J., et al. Viral gene delivery to skeletal muscle: insights on maturation-dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. Hum Gene Ther. 8:1997;371-380.
82. Yeung S., Bockhold K., Tufaro F. Efficient infection of mature skeletal muscle with herpes simplex virus vectors by using dextran sulfate as a co-receptor. Gene Ther. 6:1999;1536-1544.
83. Wolff J.A., Malone R.W., Williams P., et al. Direct gene transfer into mouse muscle in vivo. Science. 247:1990;1465-1468.
84. Danko I., Fritz J.D., Latendresse J.S., Herweijer H., Schultz E., Wolff J.A. Dystrophin expression improves myofiber survival in mdx muscle following intramuscular plasmid DNA injection. Hum Mol Genet. 2:1993;2055-2061.
85. Dunckley M.G., Wells K.E., Piper T.A., Wells D.J., Dickson G. Independent localization of dystrophin N- and C-terminal regions to the sarcolemma of mdx mouse myofibres in vivo. J Cell Sci. 107:1994;1469-1475.
86. Fritz J.D., Danko I., Roberds S.L., Campbell K.P., Latendresse J.S., Wolff J.A. Expression of deletion-containing dystrophins in mdx muscle: implications for gene therapy and dystrophin function. Pediatr Res. 37:1995;693-700.
87. Decrouy A., Renaud J.M., Davis H.L., Lunde J.A., Dickson G., Jasmin B.J. Mini-dystrophin gene transfer in mdx4cv diaphragm muscle fibers increases sarcolemmal stability. Gene Ther. 4:1997;401-408.
88. Decrouy A., Renaud J.M., Lunde J.A., Dickson G., Jasmin B.J. Mini- and full-length dystrophin gene transfer induces the recovery of nitric oxide synthase at the sarcolemma of mdx4cv skeletal muscle fibers. Gene Ther. 5:1998;59-64.
89. Tsukamoto H., Wells D., Brown S., et al. Enhanced expression of recombinant dystrophin following intramuscular injection of Epstein-Barr virus (EBV)-based mini-chromosome vectors in mdx mice. Gene Ther. July 6:(7):1999;1331-1335.
90. Braun S., Thioudellet C., Rodriguez P., et al. Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice. Gene Ther. 7:2000;1447-1457.
91. Ferrer A., Wells K.E., Wells D.J. Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy. Gene Ther. 7:2000;1439-1446.
92. Liu F., Nishikawa M., Clemens P.R., Huang L. Transfer of full-length Dmd to the diaphragm muscle of Dmd (mdx/mdx) mice through systemic administration of plasmid DNA. Mol Ther. 4:2001;45-51.
93. Vilquin J.T., Kennel P.F., Paturneau-Jouas M., et al. Electrotransfer of naked DNA in the skeletal muscles of animal models of muscular dystrophies. Gene Ther. 8:2001;1097-1107.
94. Yanagihara I., Inui K., Dickson G., et al. Expression of full-length human dystrophin cDNA in mdx mouse muscle by HVJ-liposome injection. Gene Ther. 3:1996;549-553.
95. Baranov V.S., Tarasenko O.V., Baranov V.S., et al. Expression of the human dystrophin gene in mdx mouse muscle fibers after transfection using liposomes and synthetic oligopeptides (in Russian). Genetika. 34:1998;876-882.
96. Zelenin A.V., Kolesnikov V.A., Tarasenko O.A., et al. Bacterial beta-galactosidase and human dystrophin genes are expressed in mouse skeletal muscle fibers after ballistic transfection. FEBS Lett. 414:1997;319-322.
97. Mikhailov V.M., Zelenin A.V., Shtein G.I., et al. Differentiation of muscle fibers in mdx mice after ballistic transfection of cDNA of the human dystrophin gene (in Russian). Tsitologiia. 40:1998;394-400.
98. Zelenin A.V., Tarasenko O.V., Kolesnikov V.A., et al. Expression of the human dystrophin gene in mdx mouse skeletal muscles after ballistic transfection (in Russian). Genetika. 34:1998;730-736.
99. Baranov A.N., Kiselev A.V., Ivashchenko T.E., Kashcheeva T.K., Baranov V.S. Features of transfection and expression of cDNA for the human dystrophin gene, delivered into muscles of mdx mice using MF-2 synthetic microspheres (in Russian). Genetika. 35:1999;22-27.
100. Baranov A., Glazkov P., Kiselev A., et al. Local and distant transfection of mdx muscle fibers with dystrophin and LacZ genes delivered in vivo by synthetic microspheres. Gene Ther. 6:1999;1406-1414.
101. Aihara H., Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol. 16:1998;867-870.
102. Mir L.M., Bureau M.F., Gehl J., et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA. 96:1999;4262-4267.
103. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther. 6:1999;508-514.
104. Rizzuto G., Cappelletti M., Maione D., et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci USA. 96:1999;6417-6422.
105. McMahon J.M., Signori E., Wells K.E., Fazio V.M., Wells D.J. Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase - increased expression with reduced muscle damage. Gene Ther. 8:2001;1264-1270.
106. Worgall S., Wolff G., Falck-Pedersen E., Crystal R.G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther. 8:1997;37-44.
107. Amalfitano A., Hauser M.A., Hu H., Serra D., Begy C.R., Chamberlain J.S. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol. 72:1998;926-933.
108. Mitani K., Graham F.L., Caskey C.T., Kochanek S. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci USA. 92:1995;3854-3858.
109. Chen H.H., Mack L.M., Choi S.Y., Ontell M., Kochanek S., Clemens P.R. DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. Hum Gene Ther. 10:1999;365-373.
110. Tripathy S.K., Black H.B., Goldwasser E., Leiden J.M. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med. 2:1996;545-550.
111. Yang Y., Haecker S.E., Su Q., Wilson J.M. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum Mol Genet. 5:1996;1703-1712.
112. McMahon J.M., Wells K.E., Bamfo J.E., Cartwright M.A., Wells D.J. Inflammatory responses following direct injection of plasmid DNA into skeletal muscle. Gene Ther. 5:1998;1283-1290.
113. Fassati A., Wells D.J., Walsh F.S., Dickson G. Efficiency of in vivo gene transfer using murine retroviral vectors is strain-dependent in mice. Hum Gene Ther. 6:1995;1177-1183.
114. Jooss K., Yang Y., Fisher K.J., Wilson J.M. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol. 72:1998;4212-4223.
115. Sarukhan A., Camugli S., Gjata B., von Boehmer H., Danos O., Jooss K. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol. 75:2001;269-277.
116. Sarukhan A., Soudais C., Danos O., Jooss K. Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors. J Gene Med. 3:2001;260-270.
117. Roberts R.G., Gardner R.J., Bobrow M. Searching for the 1 in 2,400,000: a review of dystrophin gene point mutations. Hum Mutat. 4:1994;1-11.
118. Hoffman E.P., Morgan J.E., Watkins S.C., Partridge T.A. Somatic reversion/suppression of the mouse mdx phenotype in vivo. J Neurol Sci. 99:1990;9-25.
119. Wilton S.D., Dye D.E., Laing N.G. Dystrophin gene transcripts skipping the mdx mutation. Muscle Nerve. 20:1997;728-734.
120. Klinman D.M., Yamshchikov G., Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol. 158:1997;3635-3639.
121. Karpati G., Carpenter S. Small-caliber skeletal muscle fibers do not suffer deleterious consequences of dystrophic gene expression. Am J Med Genet. 25:1986;653-658.
122. Greelish J.P., Su L.T., Lankford E.B., Burkman J.M., et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med. 5:1999;439-443.
123. Budker V., Zhang G., Danko I., Williams P., Wolff J. The efficient expression of intravascularly delivered DNA in rat muscle. Gene Ther. 5:1998;272-276.
124. Zhang G., Budker V., Williams P., Subbotin V., Wolff J.A. Efficient expression of naked DNA delivered intraarterially to limb muscles of nonhuman primates. Hum Gene Ther. 12:2001;427-438.
125. Taylor J., Muntoni F., Dubowitz V., Sewry C.A. The abnormal expression of utrophin in Duchenne and Becker muscular dystrophy is age related. Neuropathol Appl Neurobiol. 23:1997;399-405.
126. Nicholson L.V., Davison K., Johnson M.A., et al. Dystrophin in skeletal muscle. II. Immunoreactivity in patients with Xp21 muscular dystrophy. J Neurol Sci. 94:1989;137-146.
127. Burrow K.L., Coovert D.D., Klein C.J., et al. Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group. Neurology. 41:1991;661-666.
128. Harvey B.G., Worgall S., Ely S., Leopold P.L., Crystal R.G. Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector. Hum Gene Ther. 10:1999;2823-2837.
129. Chirmule N., Propert K., Magosin S., Qian Y., Qian R., Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6:(9):1999;1574-1583.